OrbiMed
Venture firm
OrbiMed investment thesis
Many technologies with the potential to cure disease are advancing rapidly. How long can healthy humans live, 120 years? 150 years? Our portfolio companies are working hard to find out. Filter by Sector Biopharmaceutical Diagnostics/Tools Healthcare IT Healthcare Services Medical Device Filter by Region Asia Europe / MENA North America Sort Alphabetical Newest Oldest Clear All Filters Clear All Filters Filter by Sector Biopharmaceutical Diagnostics/Tools Healthcare IT Healthcare Services Medical Device Filter by Region Asia Europe / MENA North America Sort Alphabetical Newest Oldest Apply Load More Referenced companies reflect current portfolio holdings of OrbiMed-managed private equity funds. There is no assurance that any securities discussed herein are, or will remain, in an OrbiMed-man
OrbiMed team (30)
Partners and principals at OrbiMed:
- David Bonita — sweet spot $4M
- Sven Borho — sweet spot $4M
- Evan Caplan — sweet spot $4M
- Iain Dukes — sweet spot $4M
- Michael Eggenberg — sweet spot $4M
- Lars Enstrom — sweet spot $4M
- Robert Glassman — sweet spot $4M
- Rishi Gupta — sweet spot $4M
- Sevgi Gurkan — sweet spot $4M
- Geoffrey Hsu — sweet spot $4M
- Alexandria Huynh — sweet spot $4M
- Mark Jelley — sweet spot $4M
- Chau Khuong — sweet spot $4M
- Kip Kitur — sweet spot $4M
- Kevin Koch — sweet spot $4M
- Dimitri Krainc — sweet spot $4M
- Jonathan Lee — sweet spot $4M
- Jonathan Mandelbaum — sweet spot $4M
- W. Carter Neild — sweet spot $4M
- Anat Nursella — sweet spot $4M
- Topher Orr — sweet spot $4M
- Trevor Polischuk — sweet spot $4M
- William Price — sweet spot $4M
- Matthew Rizzo — sweet spot $4M
- William Sawyer — sweet spot $4M
- Natasha Shervani — sweet spot $4M
- Jonathan Silverstein — sweet spot $4M
- Vivek Sivathanu — sweet spot $4M
- Stephen Squinto — sweet spot $4M
- Charles Steinman — sweet spot $4M
OrbiMed portfolio companies
Companies listed on OrbiMed's public materials include: Portfolio, Leadership, News & Insights, EN, CH, Filters, Load More, Acutus, link, Adaptive Biotechnologies, ADARx Pharmaceuticals, Adcendo, Adela, Adicet Bio, Advanced Enzymes, Aer Therapeutics, Aerin Medical, AIMS, AirNexis Therapeutics, AirStrip, AK Medical, Alentis Therapeutics, Alpheus Medical, Alterome Therapeutics, Alumis, AnchorDx, Angitia Biopharmaceuticals, Arcatron Mobility Private Limited, ArCHitect Therapeutics, ArriVent, ARS Pharmaceuticals, Aspen Neuroscience, Avalo Therapeutics, Avenzo Therapeutics, Averna Therapeutics, Aviceda, Avitide, Azura Opthalmics, Baili, Beijing Star Sports Medicine, Belenos Biosciences, Binx Health, BioAge Labs, Biobeat, BiomX, BlossomHill Therapeutics, BMTfemme (fka MobileODT), Bonovo Orthopedics, Braveheart Bio, Brenig Therapeutics, Candid Therapeutics, Carrot Fertility, Cellipont Bioservices, CHARM Therapeutics, Chemomab, Compass Therapeutics, Congruence Therapeutics, Convergent Therapeutics, Corteria Pharmaceuticals, Corvus Pharmaceuticals.
Is OrbiMed a fit for your round?
Upload your pitch deck and see whether anyone at OrbiMed appears in your top matches.
Find investors for your deck